{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T23:50:31Z","timestamp":1771631431870,"version":"3.50.1"},"reference-count":22,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:00:00Z","timestamp":1692662400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Takeda (Pty) Ltd South Africa"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Gaucher disease is a rare autosomal recessive glycosphingolipid storage disease that ultimately leads to reduced life expectancy. Management of Gaucher disease is challenging due to its wide genotypic and phenotypic variability and changing clinical manifestations due to effective treatment. Deliberation between experts is essential to discuss daily clinical practice and identify controversies regarding the management of Gaucher disease. The usefulness of methods like Delphi surveys is suitable for setting up consensus recommendations for different clinical scenarios.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Objectives<\/jats:title>\n<jats:p>The goal of this study was to develop an expert consensus document for the management of type 1 Gaucher disease by local experts.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Methods<\/jats:title>\n<jats:p>A modified e-Delphi was carried out to develop an expert consensus document on the management goals of type 1 Gaucher disease in South Africa. Following a literature review and input from the steering committee, 205 management goals and best practice statements were e-mailed to an independent panel for consensus development using three rounds of voting. The panel consisted of five local healthcare practitioners with expertise in Gaucher disease. Each panelist provided independent evaluations of statements sent to them via a dedicated survey platform. Panelists indicated their level of agreement on a 9-point Likert scale (1 = absolute disagreement to 9 = absolute agreement) during each round of voting. The criteria to retain a statement in the final round were \u226580% high agreement (7\u20139).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Results<\/jats:title>\n<jats:p>193 statements met the consensus threshold after three rounds of voting and were included in the final guidance document. In general, the management goals presented in this paper are in line with existing literature on the subject. Additional management goals and general recommendations on sound clinical practice, obtained from more recent research and the panelists\u2019 own clinical experience, have been included to develop a comprehensive consensus document on the management goals of type 1 Gaucher disease.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec005\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>This paper provides high-level guidance with respect to management goals, and the use of current therapies and adjunctive interventions in type 1 Gaucher disease to assist clinicians in their decisions about the appropriate management of patients in everyday clinical practice. These management goals and best practice statements might be used to inform an update to future South African guidelines on the disease.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0290401","type":"journal-article","created":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T17:23:12Z","timestamp":1692724992000},"page":"e0290401","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Management goals of type 1 Gaucher disease in South Africa: An expert Delphi consensus document on good clinical practice"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2885-3342","authenticated-orcid":true,"given":"Vernon Johan","family":"Louw","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5991-9404","authenticated-orcid":true,"given":"Ilanca","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Giraldo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2023,8,22]]},"reference":[{"issue":"1","key":"pone.0290401.ref001","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/ajh.21888","article-title":"A reappraisal of Gaucher disease-diagnosis and disease management algorithms","volume":"86","author":"PK Mistry","year":"2011","journal-title":"Am J Hematol"},{"issue":"1","key":"pone.0290401.ref002","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1182\/hematology.2020000123","article-title":"A patient with Gaucher disease and plasma cell dyscrasia: bidirectional impact","volume":"2020","author":"A Zimran","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"pone.0290401.ref003","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13023-016-0435-x","article-title":"Rethinking fatigue in Gaucher disease","volume":"11","author":"YC Zion","year":"2016","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"pone.0290401.ref004","doi-asserted-by":"crossref","first-page":"697","DOI":"10.7196\/SAMJ.5439","article-title":"South African guidelines for the management of Gaucher disease, 2011","volume":"102","author":"L Bhengu","year":"2012","journal-title":"S Afr Med J"},{"issue":"5","key":"pone.0290401.ref005","first-page":"274","article-title":"Pharmacotherapy of Gaucher Disease: Current and Future Options","volume":"43","author":"LL Bennett","year":"2018","journal-title":"P t"},{"key":"pone.0290401.ref006","unstructured":"NICE. National Institute for Health and Care Excellence. Eliglustat for treating type 1 Gaucher disease [Internet]. [London]: NICE; 2017 [updated 2023 May; cited 2023 May 25]. (Highly specialised technologies guidance [HST5]). Available from: https:\/\/www.nice.org.uk\/guidance\/hst5. 2017."},{"issue":"4","key":"pone.0290401.ref007","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ymgme.2021.06.009","article-title":"Throwing a spotlight on under-recognized manifestations of Gaucher disease: Pulmonary involvement, lymphadenopathy and Gaucheroma","volume":"133","author":"U Ramaswami","year":"2021","journal-title":"Mol Genet Metab"},{"issue":"2","key":"pone.0290401.ref008","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/17446651.2018.1445524","article-title":"Recent advances in the diagnosis and management of Gaucher disease","volume":"13","author":"SE Gary","year":"2018","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"12","key":"pone.0290401.ref009","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s12325-014-0174-0","article-title":"Management of bone disease in Gaucher disease type 1: clinical practice","volume":"31","author":"G Giuffrida","year":"2014","journal-title":"Adv Ther"},{"issue":"2","key":"pone.0290401.ref010","first-page":"157","article-title":"Clinical manifestations and management of Gaucher disease","volume":"12","author":"S Linari","year":"2015","journal-title":"Clin Cases Miner Bone Metab"},{"issue":"1","key":"pone.0290401.ref011","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s13023-020-01529-y","article-title":"Parkinson\u2019s disease in Gaucher disease patients: what\u2019s changing in the counseling and management of patients and their relatives?","volume":"15","author":"M Di Rocco","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"pone.0290401.ref012","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/jbmr.3734","article-title":"Gaucher Disease in Bone: From Pathophysiology to Practice","volume":"34","author":"D Hughes","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"2","key":"pone.0290401.ref013","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s13312-018-1249-9","article-title":"Diagnosis and Management of Gaucher Disease in India\u2014Consensus Guidelines of the Gaucher Disease Task Force of the Society for Indian Academy of Medical Genetics and the Indian Academy of Pediatrics","volume":"55","author":"RD Puri","year":"2018","journal-title":"Indian Pediatr"},{"key":"pone.0290401.ref014","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.2147\/JBM.S279756","article-title":"Novel Management and Screening Approaches for Haematological Complications of Gaucher\u2019s Disease","volume":"12","author":"P Giraldo","year":"2021","journal-title":"J Blood Med"},{"issue":"4","key":"pone.0290401.ref015","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2004.07.009","article-title":"Therapeutic goals in the treatment of Gaucher disease","volume":"41","author":"GM Pastores","year":"2004","journal-title":"Semin Hematol"},{"key":"pone.0290401.ref016","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.bcmd.2016.10.008","article-title":"Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease","volume":"68","author":"M Biegstraaten","year":"2018","journal-title":"Blood Cells Mol Dis"},{"issue":"24","key":"pone.0290401.ref017","doi-asserted-by":"crossref","first-page":"476","DOI":"10.21037\/atm.2018.11.39","article-title":"Lysosomal storage disease overview","volume":"6","author":"A. Sun","year":"2018","journal-title":"Ann Transl Med"},{"issue":"2","key":"pone.0290401.ref018","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ymgme.2015.09.002","article-title":"Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States","volume":"117","author":"M Balwani","year":"2016","journal-title":"Mol Genet Metab"},{"issue":"3","key":"pone.0290401.ref019","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ejmhg.2016.02.001","article-title":"Treatment options for patients with Gaucher disease","volume":"17","author":"RM Shawky","year":"2016","journal-title":"Egyptian Journal of Medical Human Genetics"},{"issue":"2","key":"pone.0290401.ref020","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ymgme.2021.12.009","article-title":"Screening, patient identification, evaluation, and treatment in patients with Gaucher disease: Results from a Delphi consensus","volume":"135","author":"PS Kishnani","year":"2022","journal-title":"Mol Genet Metab"},{"key":"pone.0290401.ref021","article-title":"Ethical Delphi Manual","author":"K Millar","year":"2006","journal-title":"Veterinary Record\u2014VET REC"},{"issue":"3","key":"pone.0290401.ref022","doi-asserted-by":"crossref","DOI":"10.3390\/diseases6030069","article-title":"The Importance of a Multidisciplinary Approach in the Management of a Patient with Type I Gaucher Disease","volume":"6","author":"M Torralba-Cabeza","year":"2018","journal-title":"Diseases"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0290401","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T17:23:34Z","timestamp":1692725014000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0290401"}},"subtitle":[],"editor":[{"given":"Paavani","family":"Atluri","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,8,22]]},"references-count":22,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0290401","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,22]]}}}